On the stem cell origin of cancer

American Journal of Pathology

Volumn 176, Issue 6, 2010, Pages 2584-2594

  Sell, Stewart ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BURKITT LYMPHOMA; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL DAMAGE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CHEMICAL CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INTESTINE CANCER; LIVER CANCER; LIVER CARCINOGENESIS; NONHUMAN; PAPILLOMA VIRUS; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SKIN CARCINOGENESIS; SOMATIC MUTATION; STEM CELL NICHE; STOMACH CANCER; TERATOCARCINOMA; TISSUE DIFFERENTIATION; TISSUE REGENERATION; VIRUS INFECTION; ANIMAL; CELL TRANSFORMATION; CHEMICALLY INDUCED; GENETIC EPIGENESIS; GENETICS; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; STEM CELL NICHE; STEM CELLS; TERATOCARCINOMA;

EID: 77953210095     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091064     Document Type: Review

References (103)

1. Sell S, Pierce GB: Biology of disease: maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994, 70:6-21
2. Lapidot T, Sirard C, Bormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648
3. Sutherland HJ, Blair A, Zapf RW: Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996, 87:4754-4761 (Pubitemid 26162376)
4. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737
5. Shimkin M: Contrary to Nature. NIH, USDOH, 1977
6. Bainbridge WS: The Cancer Problem. New York, The Macmillan Co., 1914
7. Recamier JCA: Recherches sur the Traitement du Cancer: par la Compression Methodique Simple ou Combinee, et sur l'Histoire General de la Meme Maladie. Paris, Gabon, 1829
8. Remak R: Ein beitrag zur entwickelungsgeschichte der krebshaften geschwulste. Deut Klin 1854, 6:70-174
9. Durante F: Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memori eed Osservazioni di Chirugia Practica 1874, 11:217-226
10. Conheim J: Congenitales, quergestreiftes muskelsarkon der nireren. Virchows Arch 1875, 65:64
11. Osler W, McCrea T: Modern Medicine: Its Theory and Practice. Philadelphia and New York, Lean & Febiger, 1913
12. Virchow R: Dir Krankhoften Geschwulste, vol II: Onkologie, pt 1. Berlin, 1863
13. Dixon FJ, Moore RA: Testicular tumors: a clinical pathological study. Cancer 1953, 1953, 6:417-443
14. Damjanov I: Pathobiology of human germ cell tumors. Recent Results Cancer Res 1991, 123:1-34
15. Solter D, Damjanov I: Teratocarcinoma and the expression of oncodevelopmental genes. Methods Cancer Res 1979, 18:277-298
16. Chan D, Sell S: Tumor markers. Teitz Textbook of Clinical Chemistry, ed 3. Edited by CA Burtis, ER Ashwood. Philadelphia, Saunders, 1999, pp 722-749
17. Peyron A: Sur la presence des cellules genitales primordiales dans les boutons embryononnaires des embryomes parthenogenetiques chez l'homme. CR Acad Sci (Paris) 1938, 206;1680-1683
18. Stevens LC: Experimental production of testicular teratomas in mice. Proc Natl Acad Sci USA 1964, 52:654-661
19. Stevens LC: Origin of testicular teratomas from primordial germ cells in mice. J Natl Cancer Inst 1967, 38:549-552
20. Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci USA 975, 72:3583-3589
21. Ilmenesee K: Reversion of malignancy and normalized differentiation of teratocarcinoma cells in mammals. Generic Mosaics and Chimeras in Mammals. Edited by LC Russel. New York, Plenum, 1978, 3-25
22. Papaioannou VE, McBurney MW, Gardner RL, Evans RL: Fate of teratocarcinoma cells injected into early mouse embryos. Nature 1975, 258:70-73
23. Papaioannou VE: Ontogen, pathology, oncology. Int J Dev Biol 1993, 37:33-37
24. Veeck LL, Zaninovic N: An Atlas of Human Blastocysts. London, Informa Health Care, 2003
25. Pierce GB, Dixon FJ: The demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 1959, 12:573-583
26. Pierce GM, Dixon FJ, Verney E: Teratocarcinogenic and tissue forming potentials of the cell types comprising neoplastic embryoid bodies. Lab Invest 1960, 9:583-602
27. Pierce GB, Shikes R, Fink LM: Cancer: a problem of developmental biology. Englewood Cliffs, NJ, Prentice Hall Inc., 1978
28. Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004, 51:1-28
29. Sun SY. Lotan R: Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002, 41:41-55
30. Pierce GB, Speers WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988, 48:1996-2004
31. Trump DL: Retinoids in bladder, testes and prostate cancer: epidemiologic, preclinical and clinical observations. Leukemia 1994, 8(Suppl 3):S50-S54
32. Sell S: Stem cells in hepatocarcinogenesis. Cell Sci Rev 2006, 3:1742-8130
33. Hill J: Cautions against the immoderate use of snuff (From Redmen DE Jr: Tobacco and cancer: the first clinical report, 1761, London). N Engl J Med 1970, 282:18-23
34. Rehn L: Blasengeschwulse bei fuchsin-arbeitern. Arch Klin Chir 1895, 50:588-600
35. Farber E: Similarities in the sequence of early histologic changes induced in the liver by ethionine, 2-acetylaminofluorene, and 3′-methyl-4-dimethylamionazobenzene. Cancer Res 1956, 16:142-148
36. Farber E: The multistep nature of cancer development. Cancer Res 1984, 44:4217-4223
37. Abelev GI: Alphafetoprotein: the genesis. Oncodev Biol Med 1983, 4:371-381
38. Sell S: Alpha-fetoprotein, stem cells, and cancer (The Abbot Award Lecture). Tumor Biol 2008, 29:161-180 (DOI: 10.1159/000143402)
39. Sell S, Leffert HL: An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. Hepatology 1982, 2:77-86 (Pubitemid 12146269)
40. Sell S, Dunsford H: Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989, 134:1347-1363 (Pubitemid 19206321)
41. Sell S, Leffert HL: Liver cancer stem cells. J Clin Oncology 2008, 26:2800-2805
42. Pott P: Chirurgical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures, and the mortification of the toes and feet. London, Hawes, Clarke and Collins, 1775
43. (see also Potter M: Percivall Pott's contribution to cancer research NCI Monograph 1963, 10:1-13
44. Yamagiwa K, Ichikawa K: Experimental study of the pathogenesis of carcinoma. J Cancer Res 1918, 3:1-29
45. Rous P: A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp Med 1911, 13:397-411
46. Rous P, Kidd JG: Conditional neoplasms and subthreshold neoplastic states. J Exp Med 1942, 73:365-372
47. Berenblum I: The mechanism of carcinogenesis: a study of the significance of cocarcinogenic action and related phenomena. Cancer Res 1941, 1:807-814
48. Boutwell RK: Some biological aspects of skin carcinogenesis. Prog Exp Tumor Res 1964, 4:207-250
49. Van Duuren BL, Sivak A, Katz C, Seidman I, Melchionne S: The effect of ageing and interval between primary and secondary treatment in two-stage carcinogenesis on mouse skin. Cancer Res 1975, 35:502-505
50. Potten CS, Morris RJ: Epithelial stem cells in vivo. J Cell Sci 1988, (Suppl)10:S45-S62
51. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H: Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008, 61:553-560
52. Borrel A: Le probleme du cancer. Bull Inst Pasteur 1907, 5:497-512, 545, 593-608, 642-662
53. Durst M, Gissmann L, Ikenberg H, zur Hausen H: A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983, 80:3812-3815
54. Deligeoroglou E, Christopoulos P, Aravantinos L, Papadias K: Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review. Eur J Gynaecol Oncol 2009, 30:128-132
55. Papanicolaou GN: Historical development of cytology as a tool in clinical medicine and in cancer research. Acta Unio Int Contra Cancrum 1958, 14:249-254
56. Sell S: Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res 2003, 63:7553-7562
57. Lee AT, Lee CG: Oncogenesis and transforming viruses: the hepatitis B virus and hepatocellular carcinoma - the etiopathogenic link. Front Biosci 2007, 12:234-245
58. Azam F, Koulaouzidis A: Hepatitis B virus and hepatocarcinogenesis. Ann Hepatol 2008, 7:125-129
59. Koike K: Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007, 22(Suppl 1):S108-S111
60. Levrero M: Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 27:3834-3847
61. Higgins GM, Anderson RM: Experimental pathology of the liver: restoration of the liver of the white rat following partial surgical removal. AMA Arch Pathol 1931, 12:186-202
62. Bucher NR, Malt RA: Regeneration of the Liver and Kidney. Boston, Little Brown and Co., 1971
63. Stowell RE, Less CW: Histochemical studies of mouse liver after single feeding of carbon tetrachloride. Arch Pathol 1973, 50:519-537
64. Wahl PN, Tandon HD, Bharadwaj TP: Acute carbon tetrachloride hepatic injury: composite histological, histochemical and biochemical study: I. Histological and histochemical studies. Acta Pathol Microbiol Scand 1955, 37A:305-314
65. Boveri R: Zur frage der entstehung maligner tumoren. Jena, Fischer, 1914
66. von Hansemann D: Das Problem der krebsmalignität. Zeitschr Krebsforsch 1920, 17:172-191
67. Nowell PC: Diagnostic and prognostic value of chromosome studies in cancer. Ann Clin Lab Sci 1974, 4:234-240
68. Rowley JD: Nonrandom chromosomal abnormalities in hematologic disorders of man. Proc Natl Acad Sci USA 1975, 72:152-156
69. Chalandon Y, Schwaller J: Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005, 90:949-968 (Pubitemid 41020298)
70. Epstein MA, Achong BG, Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964, 1:702-703
71. Cory S, Vaux DL, Harris AW, Adams JM: Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999, 597(Suppl):1681s-1692s
72. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Plakiewica RD, McNeil N, Ried T, Buchinski JF, Morse HC 3rd, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005, 65:1306-1315
73. Sell S: Leukemia: stem cells, maturation arrest and differentiation therapy. Stem Cell Rev 2005, 1:197-205
74. Drucher BJ, Ralpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian J, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 334:1031-1037
75. Drucker BJ, Cuilhot F, O'Brien SG, Gathmann I, Kantarjian HT, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA: Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417
76. Kujawski L, Talpaz M: Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leukemia Lymphoma 2007, 48:2310-2311
77. Ramirez P, DiPersio JL: Therapy options in imatinib failures. Oncologist 2008, 13:424-434
78. Quintas-Cardama A, Kantarjian H, Cortes J: Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009, 6:535-543
79. Melnick A, Licht JD: Deconstructing a disease: rARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93:3167-3215 (Pubitemid 29220886)
80. Soignet S, Fleischauer A, Pollyak T, Heller G, Warrel Jf RP: All trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long term follow-up of the New York study. Cancer Chemother Pharmacol 1997, 40:S24-S29
81. Nowak D, Stewart D, Koeffler HP: Differentiation therapy of leukemia: 3 decades of development. Blood 2009, 113:3655-3665
82. Dewel R, Lugthart S: Leukemia epigenetics: EVI1 expressing poorrisk AML associates with distinct epigenetic signatures uncovered by genome wide DNA methylation profiling. ISOBM Proceedings, 2009, 37th meeting
83. Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194:23-28
84. Fowler JF: Radiation biology as applied to radiotherapy. Curr Top Radiat Res 1966, 2:353-364
85. Senn JP, Tran-Thang C, Wodnar-Filipowicz A, Jiricny J, Fopp M, Gratwohl A, Signer E, Wever W, Moroni C: Mutation analysis of the N-ras porto-oncogene in active and remission phase of human acute leukemias. Int J Cancer 1988, 41:59-64 (Pubitemid 18049350)
86. Zaheer HA, Bagnara M, Gibson FM, Robinson G, Rutherford TR, Gordon-Smith EX: Persistence of an activating N-RAS oncogene mutation in clonogenic progenitor cells from an acute myeloid leukaemia patient in remission. Br J Haematol 1994, 86:298-302 (Pubitemid 24198991)
87. Zhu YM, Foroni L, McQuaker IG, Papaioannous M, Haynes A, Russell HH: Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer 1999, 79:1151-1157
88. Senn HP, Jiricny J, Fopp M, Scmid L, Moroni C: Relapse cell population differs from acute onset clone as shown by absence of the initially activated N-ras oncogene in a patient with acute myelomonocytic leukemia. Blood 1988, 72:931-935
89. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H, Naoe T: Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FIT3 genes compared with p53 gene. Br J Haematol 1999, 104:659-664 (Pubitemid 29143481)
90. Trott KR: Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994, 30:1-5
91. Denekamp J: Tumour stem cells: facts, interpretation and consequences. Radiother Oncol 1994, 30:6-10 (Pubitemid 24056901)
92. Eric R, Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767
93. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, Bowman BM: Evidence that APC regulates surviving expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001, 62:8664-8667 (Pubitemid 34013874)
94. Brittan M, Wright NA: Stem cell origin of cell lineages, proliferative units, and cancer in the gastrointestinal tract. Stem Cell Handbook. Edited by S Sell. Humana Press, Totowa, NJ 2004, p 329
95. Barker N, Ridgway RA, van ES JH, van de Weering M, Begthel J, van den born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H: Crypt stem cells as the cell-of-origin of intestinal cancer. Nature 2009, 457:608-611
96. Zhu L, Gibson P, Currie DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison ES, Gilbertson RJ: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607
97. Slaughter DP, Southwick HW, Smejkal W: Field "cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953, 6:963-968
98. Carlson JA, Scott D, Wharton J, Sell S: Incidental histopathologic patterns: possible evidence of "field cancerization" surrounding skin tumors. Am J Dermatopathol 2001, 223:494-497
99. Braakhuis JMB, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63:1727-1730
100. Ushijima T, Nakajima T, Maekita T: DNA methylation as a marker for the past and future. J Gastroenterol 2006, 41:401-407
101. McDonald SA, Greaves LC, Gutierrez-Gonzalez L, Rodriquez-Justo M, Deheragoda M, Leedham SJ, Taylor RW, Preston SL, Lovell M, Hunt T, Wlia G, Oufrif D, Harrison R, Novelli MR, Mitchell I, Stoker DL, Turnbull DM, Jankowski JA, Wright NA: Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 2008, 134:500-510
102. Ushijima T: Epigenetic field for cancerization. J Biochem Mol Biol 2007, 40:142-150
103. Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nature Rev Cancer 2005, 5:223-231